STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (MN-68)	OBEROTATUG RAVTANSINE
PRONUNCIATION	oh'' ber oh' tah tug rav tan' seen
THERAPEUTIC CLAIM	Antineoplastic

CHEMICAL NAMES

Immunoglobulin G1 [de-449-lysine], anti-(human lymphocyte antigen 75) (human clone OBT076_16A5 γ1-chain), disulfide with human clone OBT076_16A5 κ-chain, dimer, N^6-amide with $N^{2'}$-[4-[(3-carboxypropyl)dithio]-4-methyl-1-oxopentyl]-$N^{2'}$-deacetylmaytansine

immunoglobulin G1-kappa, anti-[*Homo sapiens* LY75 (human lymphocyte antigen 75, C-type lectin domain family 13 member B, CLEC13B, DEC-205, CD205)], *Homo sapiens* monoclonal antibody; conjugated to maytansinoid DM4; gamma1 heavy chain *Homo sapiens* (1-448) [VH (*Homo sapiens* IGHV3-15*01 (98.0%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.10.10] (26-33.51-60.99-108)) (1-119) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14 (CH1 R120>K (216) (120-217), hinge 1-15 (218-232), CH2 (233- 342), CH3 E12 (358), M14 (360) (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfide with kappa light chain *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (88.4%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'- 107') -*Homo sapiens* IGKC*01 (100%), Km3, A45.1 (153), V101 (191) (108'-214')]; dimer (228-228'':231-231'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1SV, glycoform alfa; conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM4 [*N2*'- deacetyl-*N2*'-(4-mercapto-4- methyl-1-oxopentyl)-maytansine] via the reducible SPDB linker [*N*- succinimidyl 4-(2-pyridyldithio)butanoate]

STRUCTURAL FORMULA

Heavy Chains: γ1-chain (H, H''):

```
EVQLVESGGG  LVKPGGSLRL  SCAASGFTYS  NAWMSWVRQA  PGKGLEWVGR    50
IKSKTDGGTT  DYAAPVQGRF  TISRDDSKNT  LYLQMNSLKT  EDTAVYYCTI   100
FGVVSFDYWG  QGTLVTVSSA  STKGPSVFPL  APSSKSTSGG  TAALGCLVKD   150
YFPEPVTVSW  NSGALTSGVH  TFPAVLQSSG  LYSLSSVVTV  PSSSLGTQTY   200
ICNVNHKPSN  TKVDKKVEPK  SCDKTHTCPP  CPAPELLGGP  SVFLFPPKPK   250
DTLMISRTPE  VTCVVVDVSH  EDPEVKFNWY  VDGVEVHNAK  TKPREEQYNS   300
TYRVVSVLTV  LHQDWLNGKE  YKCKVSNKAL  PAPIEKTISK  AKGQPREPQV   350
YTLPPSREEM  TKNQVSLTCL  VKGFYPSDIA  VEWESNGQPE  NNYKTTPPVL   400
DSDGSFFLYS  KLTVDKSRWQ  QGNVFSCSVM  HEALHNHYTQ  KSLSLSPG     448
```

Light chains: κ-chain (L', L''')

```
DVQMTQSPSS  LSASVGDRVT  ITCRASQSIS  DYLSWYQQRP  GKAPNLLIYA    50'
ASNLKTGVPS  RFSGSGSGTD  FTLTISTLQP  EDFATYYCQQ  SYRSPWTFGQ   100'
GTKVEIKRTV  AAPSVFIFPP  SDEQLKSGTA  SVVCLLNNFY  PREAKVQWKV   150'
DNALQSGNSQ  ESVTEQDSKD  STYSLSSTLT  LSKADYEKHK  VYACEVTHQG   200'
LSSPVTKSFN  RGEC                                           214'
```

Disulfide bridges: in red, bold text, shaded text indicates interchain (total 16 bridges)

Intra-H(C23-C104)	22-98	146-202	263-323	369-427
	22''-98''	146''-202''	263''-323''	369''-427''
Intra-L(C23-C104)	23'-88'	134'-194'		
	23'''-88'''	134'''-194'''		
Inter-H-L(h 5-CL 126)	222-214'	222''-214'''		
Inter-H-H(h 11, h 14)	228-228''	231-231''		

N-Glycosylation sites: in green bold text

299 299'' (H CH2 N84.4). Fucosylated complex bi-antennary CHO-type glycans

CDR-IMGT Regions: in bold light blue (protein sequence numbering from above sequence, not IMGT respective sequence numbering)

Heavy Chain CDR1-3 (H, H''):	26-33 (8)	51-60 (10)	99-108 (10)
	26''-33'' (8)	51''-60'' (10)	99''-108'' (10)
Light Chain CDR1-3 (L', L'''):	27'-32' (6)	50-52' (3)	89'-97' (9)
	27'''-32''' (6)	50'''-52''' (3)	89'''-97''' (9)

Lysines Modified with Drug-Linker: 50 possible substitutions as predicted by the drug manufacturer (average of 3.5 per ADC molecule, may be on heavy chains or light chains)

Possible Heavy Chain Positions (H, H'') 13, 43, 52, 54, 135, 215, 216, 224, 248, 276, 292, 322, 324, 328, 336, 342, 416
13'', 43'', 52'', 54'', 135'', 215'', 216'', 224'', 248'', 276'', 292'', 322'', 324'', 328'', 336'', 342'', 416''

Possible Light Chain Positions L', L''') 42', 55', 103', 107', 145', 188', 190', 207'
42''', 55''', 103''', 107''', 145''', 188''', 190''', 207'''

Drawing Representing OBT076 - Antibody Drug Conjugate (oberotatug ravtansine)
(modified lysines may be on heavy chains or light chains)



MOLECULAR FORMULA	$C_{6563}H_{10135}N_{1718.5}Cl_{3.5}O_{2053}S_{51}$ (unglycosylated)
MOLECULAR WEIGHT	147.71 kDa (unglycosylated)
TRADEMARK	None as yet
SPONSOR	Oxford BioTherapeutics Ltd.
CODE DESIGNATIONS	OBT076, MEN1309
CAS REGISTRY NUMBER	2641919-35-7
UNII	N2Q7V645PL

WHO NUMBER 12296

gbk